GSK updates voting rights to 4.09 bn shares – Form 6-K filing

Rhea-AI Filing Summary

GSK plc has filed a Form 6-K to report its share capital and voting rights position as of 30 June 2025 under the UK Disclosure Guidance and Transparency Rule 5.6.1R. The company’s issued share capital totals 4,315,370,199 Ordinary Shares of 31 ¼ pence each, of which 226,172,571 shares are held in treasury and therefore do not carry voting rights. After adjusting for these treasury shares, the total number of voting rights currently exercisable amounts to 4,089,197,628. Shareholders should use this denominator when determining whether their holdings cross FCA disclosure thresholds. The notice is signed by Company Secretary Victoria Whyte on 1 July 2025 and provides an email address (company.secretary@gsk.com) for notifications.

Insights

Corporate Governance Analyst

TL;DR: Routine share-capital update; no strategic or financial surprises.

This 6-K simply updates the market on GSK’s issued share count and voting-rights denominator, a standard monthly practice for UK-listed firms. No changes in economic ownership, financing structure, or corporate actions are disclosed. As such, the filing carries negligible valuation impact but ensures regulatory transparency and assists investors in threshold calculations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many voting shares does GSK (GSK) currently have outstanding?

4,089,197,628 voting rights are in issue after deducting treasury shares.

What is the total number of GSK shares held in treasury?

GSK holds 226,172,571 Ordinary Shares in treasury.

Why did GSK file this Form 6-K on 1 July 2025?

To comply with FCA Rule 5.6.1R, providing an updated denominator for shareholder disclosure calculations.

Does the filing indicate any new financing or equity issuance by GSK?

No. It is a routine capital and voting rights update with no mention of new issuance.

Where should shareholders send significant holding notifications?

Notifications can be emailed to company.secretary@gsk.com.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2025 - 11:26 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc

Total Voting Rights and Capital

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 30 June 2025 consisted of 4,315,370,199 shares of 31 ¼ pence each ('Ordinary Shares'), of which 226,172,571 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,089,197,628. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

1 July 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: July 01, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc